Abstract:Hyperuricemia is a metabolic disease caused by abnormal purine metabolism in the body. Long-term high levels of uric acid in the body will lead to gout and kidney disease. Xanthine oxidase (XOD) is a key enzyme in the pathogenesis of hyperuricemia. In this context, a series of geniposide derivatives were designed, synthesized and evaluated as xanthine oxidase inhibitors. Most of these compounds exhibited potent XOD inhibitory activities in vitro, and representatives 6a, 6c, 6g and 6j were found to be the most potent inhibitors against the enzyme with IC50 values of 2.15 ± 1.03, 1.37± 0.26, 4.14± 0.79 and 1.86± 0.13 μM, which were 33.03–158.37 fold more active than geniposide, respectively. Compounds 6a, 6c, 6g and 6j were evaluated in hyperuricemia mice, and the results demonstrated that compound 6c showed the strongest anti-hyperuricemia and renal protective activity in vivo. Subsequently, the molecular mechanism of compound 6c was studied in this investigation. In vitro cell experiments showed that compound 6c inhibited the inflammation of HK-2 cells under high uric acid conditions by inhibiting the expressions of TGF-β, TNF-α and IL-1β, and reduced the cell fibrosis by decreasing the expressions of α-SMA and Collagen I. The results of the mice experiments indicated that compound 6c efficiently decreased the level of serum uric acid (SUA) in hyperuricemia mice by inhibiting the XOD activity. Moreover, compound 6c effectively reduced the urate accumulation in the kidney and simultaneously decreased inflammation by regulating the expression of the TLR4/IκBα/NF-κB signaling pathway. In addition, consistent with cell experiments, compound 6c also reduced renal fibrosis in hyperuricemia mice, which may be due to compound 6c inhibiting the expression of inflammatory factor TGF-β. Furthermore, a molecular docking study was performed to gain insight into the binding mode of compound 6c with XOD. These results suggest that compound 6c has the potential to be developed into a novel medicine to reduce blood uric acid and treat renal diseases caused by hyperuricemia.

GlaxoSmithKline126 inhibits the wingless integrated/-catenin signaling pathway to alleviate hyperuricemia

Blockade Of Enhancer Of Zeste Homolog 2 Alleviates Renal Injury Associated With Hyperuricemia

EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.

Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats

Qi-Zhu-Xie-Zhuo-Fang reduces serum uric acid levels and ameliorates renal fibrosis in hyperuricemic nephropathy rats.

Pharmacological inhibition of Src family kinases attenuates hyperuricemic nephropathy

Blockade of ERK1/2 by U0126 Alleviates Uric Acid-Induced EMT and Tubular Cell Injury in Rats with Hyperuricemic Nephropathy.

Pharmacologic Targeting of BET Proteins Attenuates Hyperuricemic Nephropathy in Rats

Genetic and Pharmacologic Targeting of Glycogen Synthase Kinase 3 Beta Reinforces the Nrf2 Antioxidant Defense Against Podocytopathy

Genistein Ameliorates Hyperuricemia-Associated Nephropathy in Hyperuricemic Mice

Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis

Astilbin Improves Potassium Oxonate-Induced Hyperuricemia and Kidney Injury Through Regulating Oxidative Stress and Inflammation Response in Mice

Quercetin Ameliorates Hyperuricemic Nephropathy by Repressing Uric Acid Synthesis and Reabsorption in Mice and Cells

Konjac Glucomannan Improves Hyperuricemia Through Regulating Xanthine Oxidase, Adenosine Deaminase and Urate Transporters in Rats

A geniposide-phospholipid complex ameliorates posthyperuricemia chronic kidney disease induced by inflammatory reactions and oxidative stress

Pharmacological Inhibition of Fatty Acid-Binding Protein 4 Alleviated Kidney Inflammation and Fibrosis in Hyperuricemic Nephropathy

Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway

Pharmacologic Inhibiting STAT3 Delays the Progression of Kidney Fibrosis in Hyperuricemia-Induced Chronic Kidney Disease.

Targeted inhibition of TGF-β type I receptor by AZ12601011 protects against kidney fibrosis

Effect of a Novel EZH2 Inhibitor GSK126 on Prostate Cancer Cells

Gypenosides Inhibits Xanthine Oxidoreductase and Ameliorates Urate Excretion in Hyperuricemic Rats Induced by High Cholesterol and High Fat Food (Lipid Emulsion)